Truist Financial
ADMA icon

Truist Financial’s ADMA Biologics ADMA Stock Holding History

Truist Financial’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14,685
Closed -$132K – 2916
2026
Q1 		$132K Buy
14,685
+3,518
+32% +$55.5K ﹤0.01% 2694
2025
Q4 		$204K Buy
+11,167
New +$188K ﹤0.01% 2597
2025
Q2 		– Sell
-11,330
Closed -$225K – 2593
2025
Q1 		$225K Buy
+11,330
New +$196K ﹤0.01% 2306

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Truist Financial's ADMA Position: Q2 2026 in Review

Truist Financial sold out of ADMA Biologics (ADMA) in Q2 2026, closing a stake of 14,685 shares — an estimated $132K sold.

Truist Financial first reported a position in ADMA in Q1 2025 and held it in 3 quarters. The position peaked at $225K in Q1 2025. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Truist Financial reported no remaining ADMA Biologics position as of Q2 2026 after selling out during the quarter.
  • Truist Financial sold 14,685 ADMA Biologics shares in Q2 2026, an estimated $132K.
  • Truist Financial first reported a position in ADMA Biologics in Q1 2025 and held it in 3 quarters.
  • Truist Financial's ADMA Biologics position peaked at $225K in Q1 2025.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Truist Financial's 13F filing for Q2 2026, filed 28 Jul 2026.